<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        62-892-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CELEBREX 100MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CELECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Pharmaceutical LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Pharmaceutical LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER SAUDI LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Celebrex is used in adults for the relief of signs and symptoms of <strong>rheumatoid arthritis</strong>, <strong>osteoarthritis</strong> and <strong>ankylosing spondylitis, Juvenile Idiopathic Arthritis </strong>in patients 2 years and older<strong>, Acute pain and Primary Dysmenorrhea.</strong>.</p><p>&nbsp;</p><p>Celebrex belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAID), and specifically a sub-group known as cyclooxygenase‑2 &nbsp;(COX-2) inhibitors.&nbsp; Your body makes prostaglandins that may cause pain and inflammation. In conditions such as rheumatoid arthritis and osteoarthritis your body makes more of these. Celebrex acts by reducing the production of prostaglandins, thereby reducing the pain and inflammation.</p><p>&nbsp;</p><p>You should expect your medicine to start working within hours of taking the first dose, but you may not experience a full effect for several days.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You have been prescribed Celebrex by your doctor. &nbsp;The following information will help you get the best results with Celebrex.&nbsp; If you have any further questions please ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Do not take </strong><strong>Celebrex</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor if any of the following are true for you as patients with these conditions should not take Celebrex.</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to celecoxib or any of the other ingredients of this medicine (listed in section 6)<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had an allergic reaction to a group of medicines called &ldquo;sulfonamides&rdquo; (e.g. some antibiotics used to treat infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you <strong>currently</strong> have an ulcer in your stomach or intestines, or bleeding in your stomach or intestines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if as a result of taking acetylsalicylic acid or any other anti-inflammatory and pain-relieving medicine (NSAID) you have had asthma, nose polyps, severe nose congestion, or an allergic reaction such as an itchy skin rash, swelling of the face, lips, tongue or throat, breathing difficulties or wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an inflammatory disease of the intestines such as ulcerative colitis or Crohn&rsquo;s disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart failure, established ischaemic heart disease, or cerebrovascular disease, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as &ldquo;mini-stroke&rdquo;), angina, or blockages of blood vessels to the heart or brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you<em> </em>have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs</p><p><em>&nbsp;</em></p><p><strong>Warnings and precautions </strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking Celebrex:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>previously</strong> had an ulcer or bleeding in your stomach or intestines.</p><p><strong>(Do not take Celebrex</strong> if you <strong>currently</strong> have an ulcer or bleeding in your stomach or intestine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking acetylsalicylic acid (even at low dose for heart protective purposes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking antiplatelet therapies</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you use medicines to reduce blood clotting (e.g. warfarin/warfarin like anticoagulants or novel oral anti-clotting medicines, e.g. apixaban)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you use medicines called corticosteroids (e.g. prednisone)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using Celebrex at the same time as other non-acetylsalicylic NSAIDs such as&nbsp;&nbsp; ibuprofen or diclofenac. The use of these medicines together should be avoided</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you smoke, have diabetes, raised blood pressure or raised cholesterol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your heart, liver or kidneys are not working well your doctor may want to keep a regular check on you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have fluid retention (such as swollen ankles and feet)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are dehydrated, for instance due to sickness, diarrhoea or the use of diuretics (used to treat excess fluid in the body)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a serious allergic reaction or a serious skin reaction to any medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you feel ill due to an infection or think you have an infection, as Celebrex may mask a fever or other signs of infection and inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are over 65&nbsp;years of age your doctor will want to monitor you regularly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the consumption of alcohol and NSAIDs may increase the risk of gastrointestinal problems</p><p>&nbsp;</p><p>As with other NSAIDs (e.g. ibuprofen or diclofenac) this medicine may lead to an increase in blood pressure, and so your doctor may ask to monitor your blood pressure on a regular basis.</p><p>Some cases of severe liver reactions, including severe liver inflammation, liver damage, liver failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. <u>Of the cases that reported time to onset, most severe liver reactions occurred within one month of start of treatment.</u></p><p>&nbsp;</p><p>Celebrex may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant (see section on Pregnancy and breast-feeding).</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><strong>Other medicines and Celebrex</strong></p><p><em>&nbsp;</em></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines:<em> </em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dextromethorphan (used to treat coughs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACE inhibitors, angiotensin II antagonists, beta blockers and diuretics (used for high blood pressure and heart failure)&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluconazole and rifampicin (used to treat fungal and bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin or other warfarin like medicines (<em>&ldquo;</em>blood-thinning&rdquo; agents that reduce blood clotting) including newer medicines like apixaban</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (used to treat some types of depression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to treat depression, sleep disorders, high blood pressure or an irregular heartbeat&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuroleptics (used to treat some mental disorders)&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (used to treat rheumatoid arthritis, psoriasis and leukaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine (used to treat epilepsy/seizures and some forms of pain or depression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Barbiturates (used to treat epilepsy/seizures and some sleep disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin and tacrolimus (used for immune system suppression e.g. after transplants)</p><p>&nbsp;</p><p>&nbsp;</p><p>Celebrex can be taken with low dose acetylsalicylic acid (75&nbsp;mg or less daily). Ask your doctor for advice before taking both medicines together.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>Celebrex must not be used by women who are pregnant or can become pregnant<em> </em>(i.e. women of child bearing potential who are not using adequate contraception) during ongoing treatment. If you become pregnant during treatment with Celebrex you should discontinue the treatment and contact your doctor for alternative treatment.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Celebrex must not be used during breast-feeding.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>NSAIDs, including Celebrex, may make it more difficult to become pregnant. You should tell your doctor if you are planning to become pregnant or if you have problems becoming pregnant.</p><p><em>&nbsp;</em></p><p><strong>Driving and using machines</strong></p><p>You should be aware of how you react to Celebrex before you drive or operate machinery.&nbsp; If you feel dizzy or drowsy after taking Celebrex, do not drive or operate machinery until these effects wear off.</p><p><em>&nbsp;</em></p><p><strong>Celebrex contains lactose</strong></p><p>Celebrex contains <strong>lactose</strong> (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p><strong>Celebrex contains sodium </strong></p><p>This medicine contains less than 1 mmol <strong>sodium</strong> (23&nbsp;mg) per capsule, that is to say essentially &lsquo;sodium-free</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.&nbsp; If you think or feel that the effect of Celebrex is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>Your doctor will tell you what dose you should take. As the risk of side effects associated with heart problems may increase with dose and duration of use, it is important that you use the lowest dose that controls your pain and you should not take Celebrex for longer than necessary to control symptoms.</p><p>&nbsp;</p><p><u>Method of administration:</u></p><p><u>&nbsp;</u></p><p><strong>Celebrex is for oral use.</strong> The capsules can be taken at any time of the day, with or without food. However, try to take each dose of Celebrex at the same time each day.</p><p>If you have difficulty swallowing capsules: The entire capsule contents can be sprinkled onto a level teaspoon of semi-solid food (such as cool or room temperature applesauce, rice gruel, yogurt or mashed banana) and swallowed immediately with a drink approximately 240&nbsp;ml of water.</p><p>&nbsp;</p><p>To open the capsule, hold upright to contain the granules at the bottom then gently squeeze the top and twist to remove, taking care not to spill the contents. <strong>Do not chew or crush the granules.</strong></p><p>&nbsp;</p><p>Contact your doctor within two weeks of starting treatment if you do not experience any benefit.</p><p><u>&nbsp;</u></p><p><u>The recommended dose is:</u></p><p><strong>&nbsp;</strong></p><p><strong>For osteoarthritis</strong> the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400&nbsp;mg, if needed.</p><p>The dose is usually:</p><p>n&nbsp; one 200&nbsp;mg capsule once a day; or</p><p>n&nbsp; one 100&nbsp;mg capsule twice a day.</p><p>&nbsp;</p><p><strong>For rheumatoid arthritis</strong> the recommended dose is 200&nbsp;mg each day, increased by your doctor to a maximum of 400&nbsp;mg, if needed.</p><p>The dose is usually:</p><p>n&nbsp; one 100&nbsp;mg capsule twice a day.</p><p>&nbsp;</p><p><strong>For</strong> <strong>ankylosing spondylitis</strong> the recommended dose is 200&nbsp;mg each day, increased by your doctor to a maximum of 400&nbsp;mg, if needed.</p><p>The dose is usually:</p><p>n&nbsp; one 200&nbsp;mg capsule once a day; or</p><p>one 100&nbsp;mg capsule twice a day.</p><p>&nbsp;</p><p><strong>For Juvenile Idiopathic Arthritis: </strong>the dosage for paediatric patients (age 2 years and older) is based on weight.</p><p>n&nbsp; For patients &gt;10 kg to &lt;25 kg the recommended dose is 50 mg twice daily.</p><p>n&nbsp; For patients &gt;25 kg the recommended dose is 100 mg twice daily.</p><p>n&nbsp; For patients who have difficulty swallowing capsules, the contents of a CELEBREX capsule can be added to applesauce. The entire capsule contents are carefully emptied onto a level teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled capsule contents on applesauce are stable for up to 6 hours under refrigerated conditions (2-8&deg; C).</p><p><strong>&nbsp;</strong></p><p><strong>For Acute Pain and Treatment of Primary Dysmenorrhea: </strong>For management of Acute Pain and Treatment of Primary Dysmenorrhea, the dosage is</p><p>n&nbsp; 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily as needed.</p><p><strong>&nbsp;</strong></p><p><strong>Kidney or liver problems</strong>: make sure your doctor knows if you have liver or kidney problems as you may need a lower dose.&nbsp;</p><p>&nbsp;</p><p><strong>The elderly, especially those with a weight less than 50&nbsp;kg:</strong> if you are over 65&nbsp;years of age and especially if you weigh less than 50&nbsp;kg, your doctor may want to monitor you more closely.<strong>&nbsp;</strong></p><p><strong>If you take more </strong><strong>Celebrex</strong><strong> than you should </strong></p><p>You should not take more capsules than your doctor tells you to. If you take too many capsules contact your doctor, pharmacist or hospital and take your medicine with you.</p><p>&nbsp;</p><p><strong>If you forget to take </strong><strong>Celebrex</strong><em> </em></p><p>If you forget to take a capsule, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose.</p><p><em>&nbsp;</em></p><p>If you stop taking Celebrex</p><p>Suddenly stopping your treatment with Celebrex may lead to your symptoms getting worse.&nbsp; Do not stop taking Celebrex unless your doctor tells you to.&nbsp; Your doctor may tell you to reduce the dose over a few days before stopping completely.</p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p>&nbsp;</p><p><strong>The side effects listed below were observed in arthritis patients who took Celebrex. Side effects marked with an asterisk (*) are listed below at the higher frequencies that occurred in patients who took Celebrex to prevent colon polyps. Patients in these studies took Celebrex at high doses and for a long duration.</strong></p><p>&nbsp;</p><p><strong>If any of the following happen, stop taking </strong><strong>Celebrex</strong> <strong>and tell your doctor immediately:</strong></p><p><strong>If you have: </strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems such as pain in the chest</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe stomach pain or any sign of bleeding in the stomach or intestines, such as passing black or bloodstained stools, or vomiting blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a skin reaction such as rash, blistering or peeling of the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure (symptoms may include nausea (feeling sick), diarrhoea, jaundice (your skin or the whites of your eyes look yellow)).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure, including worsening of existing high blood pressure *</p><p><strong>&nbsp;</strong></p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid build up with swollen ankles, legs and/or hands</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath*, sinusitis (sinus inflammation, sinus infection, blocked or painful sinuses), blocked or runny nose, sore throat, coughs, colds, flu-like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, difficulty sleeping &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting*, stomach ache, diarrhoea, indigestion, wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty swallowing*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of existing allergies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accidental injury</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure, palpitations (awareness of heart beat), fast heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities in liver-related blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities in kidney-related blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (changes in red blood cells that can cause fatigue and breathlessness)<strong><em> </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, depression, tiredness, drowsiness, tingling sensations (pins and needles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High levels of potassium in blood test results (can cause nausea (feeling sick), fatigue, muscle weakness or palpitations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired or blurred vision, ringing in the ears, mouth pain and sores, difficulty hearing*&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, burping, stomach inflammation (indigestion, stomach ache or vomiting), worsening of inflammation of the stomach or intestine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leg cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised itchy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin discolouration (bruising)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain (generalised pain not related to the heart)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Face swelling</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcers (bleeding) in the stomach, gullet or intestines; or rupture of the intestine (can cause stomach ache, fever, nausea, vomiting, intestinal blockage), dark or black stools, inflammation of the pancreas (can lead to stomach pain), inflammation of the gullet (oesophagus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of sodium in the blood (a condition known as hyponatraemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced number of white blood cells (which help to protect the body from infection) or blood platelets (increased chance of bleeding or bruising)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty coordinating muscular movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling confused, changes in the way things taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of hair</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hallucinations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute reaction that may lead to lung inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clot in the blood vessels in the lungs. Symptoms may include sudden breathlessness, sharp pains when you breathe or collapse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding of the stomach or intestines (can lead to bloody stools or vomiting), inflammation of the intestine or colon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe liver inflammation (hepatitis). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menstrual disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, mouth, tongue or throat, or difficulty swallowing</p><p>&nbsp;</p><p><strong>Very rare: may </strong><strong>affect up to 1 in 10,000 people</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reactions (including potentially fatal anaphylactic shock)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin conditions such as Stevens-Johnson syndrome, exfoliative dermatitis and toxic epidermal necrolysis (can cause rash, blistering or peeling of the skin) and acute generalised exanthematous pustulosis (symptoms include the skin becoming red with swollen areas covered in numerous small pustules)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A delayed allergic reaction with possible symptoms such as rash, swelling of the face, fever, swollen glands, and abnormal test results (e.g., liver, blood cell (eosinophilia, a type of raised white blood cell count))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding within the brain causing death</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Meningitis (inflammation of the membrane around the brain and spinal cord)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver failure, liver damage and severe liver inflammation (fulminant hepatitis) (sometimes fatal or requiring liver transplant). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver problems (such as cholestasis and cholestatic hepatitis, which may be accompanied by symptoms such as discoloured stools, nausea and yellowing of the skin or eyes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the kidneys and other kidney problems (such as nephrotic syndrome and minimal change disease, which may be accompanied by symptoms such as water retention (oedema), foamy urine, fatigue and a loss of appetite)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of epilepsy (possible more frequent and/or severe seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blockage of an artery or vein in the eye leading to partial or complete loss of vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflamed blood vessels (can cause fever, aches, purple blotches on the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduction in the number of red and white blood cells and platelets (may cause tiredness, easy bruising, frequent nose bleeds and increased risk of infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain and weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired sense of smell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of taste</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased fertility in females, which is usually reversible on discontinuation of the medicine</p><p><em>&nbsp;</em></p><p><strong>In clinical studies not associated with arthritis or other arthritic conditions, where Celebrex was taken at doses of 400&nbsp;mg per day for up to 3&nbsp;years, the following additional side effects have been observed:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart problems: angina (chest pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach problems: irritable bowel syndrome (can include stomach ache, diarrhoea, indigestion, wind)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney stones (which may lead to stomach or back pain, blood in urine), difficulty passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deep vein thrombosis (blood clot usually in the leg, which may cause pain, swelling or redness of the calf or breathing problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach problems: stomach infection&nbsp;(which can cause irritation and ulcers of the stomach and intestines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower limb fracture</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles, skin infection, eczema (dry itchy rash), pneumonia (chest infection (possible cough, fever, difficulty breathing))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Floaters in the eye causing blurred or impaired vision, vertigo due to inner ear troubles, sore, inflamed or bleeding gums, mouth sores</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive urination at night, bleeding from piles/ haemorrhoids, frequent bowel movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatty lumps in skin or elsewhere, ganglion cyst (harmless swellings on or around joints and tendons in the hand or foot), difficulty speaking, abnormal or very heavy bleeding from the vagina, breast pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High levels of sodium in blood test results</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:333px"><tbody><tr><td style="vertical-align:top; width:330px"><p>National Pharmacovigilance Centre ( NPC )</p><p>&nbsp;</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep Celebrex out of the reach and sight of children.</p><p>Do not use Celebrex after the expiry date stated on the blister and carton.&nbsp; The expiry date refers to the last day of that month.</p><p>Store Celebrex below 30<sup>o </sup>C.</p><p>The sprinkled capsule contents on applesauce, rice gruel or yogurt are stable for up to 6 hours under refrigerated conditions (2-8&deg; C/ 35-45&deg; F).<strong> </strong>The sprinkled capsule contents on mashed banana should not be stored under refrigerated conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is celecoxib.</p><p>1&nbsp;capsule contains 100 mg, 200 mg or 400&nbsp;mg celecoxib.</p><p>&nbsp;</p><p><u>The other ingredients are:</u></p><p>Lactose monohydrate, sodium laurilsulfate, polyvidone, croscarmellose sodium, magnesium stearate.</p><p>Capsule shells contain gelatin, titanium dioxide E171, sodium laurilsulfate and sorbitan monolaurate.</p><p>Printing ink contains ferric oxide E172 for 200 mg capsule, Aluminum Lake (E132) for 100 mg capsule, and both Ferric Oxide E172 and Aluminum Lake (E132) are used for 400 mg capsule.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Celebrex is available as hard capsules.

Opaque, white with two blue bands marked 7767 and 100 (Celebrex 100 mg).
Opaque, white with two gold bands marked 7767 and 200 (Celebrex 200 mg).
Opaque, white with two green bands marked 7767 and 400 (Celebrex 400 mg).
The capsules are packaged in clear or opaque PVC/aluminium blisters.

Celebrex 100 mg is contained in packs of 20 Capsules. 
Celebrex 200 mgis contained in packs of 10 or 20 Capsules. 
Celebrex 400 mg is contained in pack of 10 Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Saudi Limited for Celebrex 100 and Celebrex 200 mg Capsules</p><p>Pfizer Inc. &ndash; USA for Celebrex 400 mg Capsules</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Pfizer Saudi Limited for Celebrex 200 mg Capsules</p><p>Pfizer Pharmaceutical LLC, Vega Baja &ndash; PR- USA for Celebrex 100 mg and Celebrex 400 mg Capsules</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستخدم سيليبريكس في البالغين لتخفيف علامات وأعراض <strong>التهاب المفاصل الروماتويدي</strong>، <strong>والفصال العظمي</strong>، و<strong>التهاب الفقار المقسط، والتهاب المفاصل اليفعي مجهول السبب </strong>في المرضى بعمر عامين أو أكبر<strong>، والألم الحاد وعسر الطمث الأولي.</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي سيليبريكس إلى مجموعة من الأدوية تسمى مضادات الالتهاب غير الستيرويدية (NSAID)، وخاصة المجموعة الفرعية المعروفة باسم مثبطات سيكلو-أوكسيجيناز-٢ (COX-2).&nbsp; يقوم جسمك بتصنيع البروستاجلاندينات التي قد تسبب الألم والالتهاب. وفي حالات كالتهاب المفاصل الروماتويدي والتهاب الفصال العظمي، يصنّع جسمك المزيد من هذه المواد. يعمل سيليبريكس على خفض إنتاج البروستاجلاندينات وبالتالي يحد من الألم والالتهاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن تتوقع أن يبدأ الدواء في العمل خلال ساعات من تناول الجرعة الأولى، ولكن قد لا تشعر بتأثير كامل إلا بعد مرور عدة أيام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لقد وصف لك طبيبك سيليبريكس.&nbsp; ستساعدك المعلومات التالية على تحقيق أفضل نتائج للعلاج بسيليبريكس.&nbsp; إذا كان لديك المزيد من الأسئلة، يرجى طرحها على طبيبك أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ- موانع استعمال سيليبريكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك إذا ما انطبقت أي من الحالات التالية عليك، حيث يحظر استخدام سيليبريكس مع المرضى المصابين بهذه الحالات.</strong></p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه سيليكوكسيب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦)<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن أصبت بتفاعل حساسية تجاه مجموعة من الأدوية تُدعى &quot;السلفوناميدات&quot; (مثل بعض المضادات الحيوية المستخدمة لعلاج العدوى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني <strong>حاليًا</strong> من قرحة في المعدة أو الأمعاء، أو من نزيف في المعدة أو الأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن أصبت بالربو، أو بسلائل أنفية، أو احتقان شديد بالأنف، أو تفاعل حساسية مثل طفح جلدي مصحوب بحكة، أو تورم الوجه، أو الشفتين، أو اللسان، أو الحلق، أو صعوبات التنفس، أو الأزيز، وذلك نتيجة لتناول حمض الأسيتيل ساليسيليك أو أي من الأدوية الأخرى المسكنة للآلام والمضادة للالتهاب (NSAID)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين طفلكِ رضاعة طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض شديد في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض شديد في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض التهابي في الأمعاء مثل التهاب القولون التقرحي أو داء كرون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بفشل القلب أو بمرض قلبي إقفاري مؤكد أو بمرض دماغي وعائي، مثل أن يكون قد تم تشخيص إصابتك بأزمة قلبية، أو بسكتة دماغية، أو بأزمة إقفارية عابرة (انخفاض مؤقت في تدفق الدم إلى الدماغ، وتعرف أيضًا باسم &quot;سكتة دماغية بسيطة&quot;)، أو بذبحة صدرية أو بانسداد الأوعية الدموية المؤدية إلى القلب أو الدماغ</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني أو سبق أن عانيت من مشكلات متعلقة بالدورة الدموية (مرض شرياني طرفي) أو إذا سبق أن خضعت لجراحة على شرايين الساقين</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>ب- الاحتياطات عند استعمال سيليبريكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى الطبيب أو الصيدلي قبل تناول سيليبريكس:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>سبق </strong>أن أصبت بقرحة أو نزيف في المعدة أو الأمعاء.</p><p dir="RTL"><strong>(لا تتناول سيليبريكس </strong>إذا كنت تعاني <strong>حاليًا</strong> من قرحة أو نزيف في المعدة أو الأمعاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حمض الأسيتيل ساليسيليك (حتى وإن كان بجرعة منخفضة بغرض وقاية القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول العلاجات المضادة للصفيحات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أدوية لتقليل تجلط الدم (مثل وارفارين/مضادات التجلط الشبيهة بوارفارين أو مضادات التجلط الحديثة التي تؤخذ عن طريق الفم مثل أبيكسابان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أدوية تسمى الستيرويدات القشرية (مثل بريدنيزون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم سيليبريكس بالتزامن مع أحد مضادات الالتهاب الأخرى غير الستيرويدية وغير المشتقة من حمض الأسيتيل ساليسيليك، مثل إيبوبروفين أو ديكلوفيناك. ينبغي تجنب استخدام هذه الأدوية معًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تدخن، أو كنت مصابًا بداء السكري، أو تعاني من ارتفاع ضغط الدم، أو ارتفاع الكوليسترول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان هناك خلل في وظائف القلب أو الكبد أو الكلى لديك، فقد يرغب طبيبك في متابعة حالتك بانتظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من احتباس السوائل (كتورم الكاحلين والقدمين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الجفاف، على سبيل المثال نتيجة للمعاناة من مرض ما أو من الإسهال أو لاستخدام مدرات البول (المستخدمة لعلاج تراكم السوائل الزائدة في الجسم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن أصبت بتفاعل حساسية خطير أو تفاعل جلدي خطير تجاه أي أدوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بالمرض بسبب إصابتك بعدوى أو تعتقد أنك كذلك، حيث قد يخفي سيليبريكس علامات الحمى أو غيرها من علامات العدوى والالتهاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك يزيد عن ٦٥ عامًا، فسيرغب طبيبك في مراقبة حالتك بانتظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يزيد تناول الكحوليات ومضادات الالتهاب غير الستيرويدية من خطر التعرض لمشكلات معدية معوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال مع مضادات الالتهاب غير الستيرويدية الأخرى (مثل إيبوبروفين أو ديكلوفيناك)، قد يسبب هذا الدواء ارتفاع ضغط الدم، لذا فقد يطلب طبيبك مراقبة ضغط دمك بشكل منتظم.</p><p dir="RTL">تم الإبلاغ عن بعض حالات الإصابة بتفاعلات كبدية شديدة مع استخدام سيليكوكسيب، بما في ذلك التهاب الكبد وتلف الكبد وفشل الكبد الشديد (كان بعضها مميتًا أو تطلب إجراء زرع للكبد). <u>وفي الحالات التي أبلغ فيها بالمدة السابقة لظهور التفاعلات، حدثت معظم التفاعلات الكبدية الشديدة خلال شهر واحد من بدء العلاج.</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يجعل سيليبريكس إمكانية الحمل أكثر صعوبة. ينبغي عليكِ إبلاغ طبيبكِ إذا كنتِ تخططين للحمل أو إذا كنتِ تواجهين صعوبات في حدوث الحمل (انظري القسم الخاص بالحمل والرضاعة الطبيعية).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى:<em> </em></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديكستروميثورفان (يستخدم لعلاج السعال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الإنزيم المحول للأنجيوتنسين (ACE)، ومضادات الأنجيوتنسين II، وحاصرات البيتا، ومدرات البول (تستخدم لعلاج ضغط الدم المرتفع وفشل القلب)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول وريفامبيسين (يستخدمان لعلاج حالات العدوى الفطرية والبكتيرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين أو الأدوية الأخرى المشابهة لوارفارين (العوامل &quot;المسيلة للدم&quot; التي تقلل من تجلط الدم) بما في ذلك الأدوية الأحدث مثل أبيكسابان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (يستخدم لعلاج بعض أنواع الاكتئاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المستخدمة لعلاج الاكتئاب، أو اضطرابات النوم، أو ضغط الدم المرتفع، أو ضربات القلب غير المنتظمة&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الذهان (تستخدم لعلاج بعض الاضطرابات العقلية)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (يستخدم لعلاج التهاب المفاصل الروماتويدي والصدفية وابيضاض الدم)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>كاربامازيبين (يستخدم لعلاج الصرع/النوبات وبعض أنواع الألم أو الاكتئاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الباربيتيورات (تستخدم لعلاج الصرع/النوبات وبعض اضطرابات النوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين وتاكروليموس (يستخدمان لتثبيط الجهاز المناعي مثل الاستخدام بعد عمليات زرع الأعضاء)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تناول سيليبريكس مع جرعات منخفضة من حمض الأسيتيل ساليسيليك (٧٥ ملجم أو أقل يوميًا). استشر طبيبك قبل تناول كلا الدواءين معًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د- الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب عدم استخدام سيليبريكس من قِبل السيدات الحوامل أو اللاتي بإمكانهن الحمل<em> </em>(أي السيدات القادرات على الإنجاب اللاتي لا يستخدمن وسيلة ملائمة لمنع الحمل) أثناء العلاج. إذا أصبحتِ حاملًا أثناء العلاج بسيليبريكس، ينبغي لكِ إيقاف العلاج والاتصال بطبيبكِ ليصف لكِ علاجًا بديلًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">يجب عدم استخدام سيليبريكس أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">قد تجعل مضادات الالتهاب غير الستيرويدية، بما في ذلك سيليبريكس، إمكانية الحمل أكثر صعوبة. ينبغي لكِ إبلاغ طبيبكِ إذا كنتِ تخططين للحمل أو إذا كنتِ تواجهين مشكلات في أن تصبحي حاملًا.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>هـ- تأثير سيليبريكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب أن تكون على دراية بكيفية تفاعل جسمك مع سيليبريكس قبل الشروع في القيادة أو تشغيل الآلات.&nbsp; إذا شعرت بالدوار أو النعاس بعد تناول سيليبريكس، فلا تقم بالقيادة أو تشغيل الآلات حتى تزول هذه الآثار.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>و- معلومات هامة حول بعض مكونات سيليبريكس</strong></p><p dir="RTL"><strong>يحتوي سيليبريكس على اللاكتوز</strong></p><p dir="RTL">يحتوي سيليبريكس على اللاكتوز (نوع من السكر). إذا أخبرك طبيبك بأنك مصاب بعدم تحمل لبعض السكريات، فتواصل معه قبل تناول هذا المنتج الدوائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سيليبريكس على الصوديوم</strong></p><p>يحتوي هذا الدواء على أقل من ۱ مليمول من <strong>الصوديوم</strong> (۲۳ ملجم) في كل قرص، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على استخدام هذا الدواء بالضبط كما أخبرك طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.&nbsp; إذا كنت تعتقد أو تشعر أن تأثير سيليبريكس قوي أو ضعيف بشكل زائد، فتحدث مع طبيبك أو الصيدلي حول هذا الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك بالجرعة التي ينبغي لك تناولها. نظرًا لأن خطر الإصابة بالآثار الجانبية المرتبطة بمشكلات القلب قد يزداد مع الجرعة ومدة الاستخدام، فمن المهم أن تستخدم أقل جرعة ممكنة يمكنها السيطرة على الألم وألّا تتناول سيليبريكس لمدة أطول من اللازم للسيطرة على الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>طريقة الاستعمال:</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>سيليبريكس مخصص للاستخدام عن طريق الفم.</strong> يمكن تناول الكبسولات في أي وقت من اليوم، مع الطعام أو دونه. ومع ذلك، حاول تناول جرعات سيليبريكس في الوقت نفسه من كل يوم.</p><p dir="RTL">إذا كنت تواجه صعوبة في بلع الكبسولات: يمكن نثر محتويات الكبسولة بالكامل على مقدار ملعقة صغيرة مسطحة من طعام شبه صلب (مثل مهروس التفاح أو عصيدة الأرز أو الزبادي أو الموز المهروس، على أن تكون هذه الأطعمة باردة أو بدرجة حرارة الغرفة) وبلعها على الفور مع حوالي ٢٤٠ مل من الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لفتح الكبسولة، أمسك الكبسولة بوضع قائم بحيث تكون الحبيبات في الجزء السفلي ثم قم بالضغط برفق على الجزء العلوي وقم بإدارته لإزالته، مع مراعاة عدم انسكاب المحتويات. <strong>لا تمضغ الحبيبات أو تسحقها.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تواصل مع طبيبك خلال أسبوعين من بدء العلاج إذا لم تشعر بأي تحسن.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الجرعة الموصى بها هي:</u></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>لعلاج الفصال العظمي</strong>، الجرعة الموصى بها هي ٢٠٠ ملجم يوميًا، قابلة للزيادة من قِبل طبيبك إلى ٤٠٠ ملجم بحد أقصى، إذا اقتضت الحاجة.</p><p dir="RTL">تبلغ الجرعة المعتادة:</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة ٢٠٠ ملجم مرة في اليوم؛</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو كبسولة واحدة ١٠٠ ملجم مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج التهاب المفاصل الروماتويدي</strong>، الجرعة الموصى بها هي ٢٠٠ ملجم يوميًا، قابلة للزيادة من قِبل طبيبك إلى ٤٠٠ ملجم بحد أقصى، إذا اقتضت الحاجة.</p><p dir="RTL">تبلغ الجرعة المعتادة:</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة ١٠٠ ملجم مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج</strong> <strong>التهاب الفقار المقسط</strong>، الجرعة الموصى بها هي ٢٠٠ ملجم يوميًا، قابلة للزيادة من قِبل طبيبك إلى ٤٠٠ ملجم بحد أقصى، إذا اقتضت الحاجة.</p><p dir="RTL">تبلغ الجرعة المعتادة:</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة ٢٠٠ ملجم مرة في اليوم؛</p><p dir="RTL">أو كبسولة واحدة ١٠٠ ملجم مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج التهاب المفاصل اليفعي مجهول السبب: </strong>تعتمد الجرعة للمرضى من الأطفال (بعمر عامين وأكبر) على الوزن.</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للمرضى الذين يبلغ وزنهم أكثر من ١٠ كلجم إلى أقل من ٢٥ كلجم، تكون الجرعة الموصى بها هي ٥٠ ملجم مرتين يوميًا.</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أما المرضى بوزن أكبر من ٢٥ كلجم، تكون الجرعة الموصى بها ١٠٠ ملجم مرتين يوميًا.</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للمرضى الذين يعانون من صعوبة في بلع الكبسولات، يمكن إضافة محتويات كبسولة سيليبريكس إلى مهروس التفاح. يتم تفريغ محتويات الكبسولة بالكامل بعناية على مقدار ملعقة صغيرة مسطحة من مهروس التفاح البارد أو في درجة حرارة الغرفة، ثم يتم تناولها على الفور مع الماء. وتكون محتويات الكبسولة التي تم نثرها على مهروس التفاح مستقرة لمدة تصل إلى ٦ ساعات في البراد (الثلاجة) (من درجتين مئويتين إلى ٨ درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للسيطرة على الألم الحاد وعلاج عسر الطمث الأولي: </strong>للسيطرة على الألم الحاد وعلاج عسر الطمث الأولي، تكون الجرعة</p><p dir="RTL">n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٤٠٠ ملجم في البداية، تعقبها جرعة إضافية قدرها ٢٠٠ ملجم عند الحاجة في اليوم الأول. وفي الأيام اللاحقة، تكون الجرعة الموصى بها هي ٢٠٠ ملجم مرتين يوميًا حسب الحاجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشكلات الكلى أو الكبد</strong>: احرص على إخبار طبيبك إذا كنت تعاني من مشكلات بالكبد أو الكلى حيث قد تحتاج إلى استخدام جرعات أقل.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المسنون، خاصة أولئك الذين تقل أوزانهم عن ٥٠ كلجم:</strong> إذا كان عمرك يزيد عن ٦٥ عامًا وخاصة إذا كان وزنك أقل من ٥٠ كلجم، فقد يرغب طبيبك في متابعة حالتك عن كثب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ- الجرعة الزائدة من سيليبريكس</strong></p><p dir="RTL">ينبغي عدم تناول عدد كبسولات أكثر مما وصفه لك طبيبك. إذا ما تناولت عددًا من الكبسولات أكثر مما ينبغي، فاتصل بطبيبك أو الصيدلي أو المستشفى وخذ دواءك معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب- نسيان تناول جرعة سيليبريكس</strong><em> </em></p><p dir="RTL">إذا نسيت تناول إحدى الكبسولات، فتناولها بمجرد أن تتذكر. لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL"><em>&nbsp;</em></p><p>ج- التوقف عن تناول سيليبريكس</p><p dir="RTL">قد يؤدي الإيقاف المفاجئ للعلاج بسيليبريكس إلى تدهور أعراضك.&nbsp; لا تتوقف عن تناول سيليبريكس ما لم يخبرك طبيبك بذلك. &nbsp;قد يطلب منك طبيبك تقليل الجرعة على مدار بضعة أيام قبل التوقف تمامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظت الآثار الجانبية المدرجة أدناه لدى مرضى التهاب المفاصل الذين تناولوا سيليبريكس. الآثار الجانبية الموضحة بعلامة النجمة (*) مدرجة أدناه بأعلى معدلات تكرار حدثت لدى المرضى الذين تناولوا سيليبريكس بغرض الوقاية من سلائل القولون. تناول المرضى المشاركون في هذه الدراسات سيليبريكس بجرعات مرتفعة ولمدة طويلة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أصبت بأي مما يلي، فأوقف تناول سيليبريكس</strong> <strong>وأخبر طبيبك على الفور:</strong></p><p dir="RTL"><strong>إذا أصبت: </strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>بتفاعل حساسية، مثل الطفح الجلدي، أو تورم الوجه، أو الأزيز، أو صعوبة التنفس</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>بمشكلات قلبية مثل ألم الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بآلام شديدة في المعدة أو أي علامة على وجود نزيف في المعدة أو الأمعاء، كوجود دم في البراز أو براز بلون أسود أو تقيؤ دم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بتفاعل جلدي، مثل الطفح الجلدي أو تبثر أو تقشر الجلد</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>بفشل الكبد (قد تتضمن أعراضه الغثيان أو الإسهال أو اليرقان (اصفرار الجلد أو بياض العينين)).</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع، بما في ذلك تفاقم حالة ضغط الدم المرتفع الموجودة بالفعل *</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم السوائل داخل الجسم مع تورم الكاحلين و/أو الساقين و/أو اليدين</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس*، التهاب الجيوب (التهاب أو عدوى أو انسداد أو ألم الجيوب)، انسداد أو رشح الأنف، ألم الحلق، السعال، نزلات البرد، أعراض مشابهة للإنفلوانزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار، صعوبة النوم&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء*، ألم المعدة، الإسهال، عسر الهضم، الغازات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (الشعور بالرغبة في التقيؤ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم حالات الحساسية الموجودة بالفعل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة العرضية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>السكتة الدماغية*</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>فشل القلب، الخفقان (الإحساس بقوة نبض القلب)، معدل نبضات قلب سريع</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>نتائج غير طبيعية لفحوصات الدم المتعلقة بالكبد</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>نتائج غير طبيعية لفحوصات الدم المتعلقة بالكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (تغيرات في خلايا الدم الحمراء يمكن أن تسبب الإرهاق وانقطاع النفس)<strong><em> </em></strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>القلق، الاكتئاب، التعب، النعاس، إحساس بالتنميل (الشكشكة والوخز)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ارتفاع مستويات البوتاسيوم في نتائج فحوصات الدم (قد يسبب الغثيان أو الإرهاق أو ضعف العضلات أو الخفقان)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>اختلال أو تغيم الرؤية، طنين في الأذن، ألم وتقرحات الفم، صعوبة السمع*&nbsp;&nbsp;</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الإمساك، التجشؤ، التهاب المعدة (عسر الهضم، أو ألم المعدة، أو القيء)، تدهور حالة التهاب المعدة أو الأمعاء</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الشعور بشد في عضلات الساق</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الطفح الجلدي البارز المثير للحكة (الشرى)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>التهاب العين</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>صعوبة التنفس</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>تغير لون الجلد (التكدم)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ألم الصدر (ألم معمم غير مرتبط بالقلب)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>تورم الوجه</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح (نزيف) في المعدة أو المريء أو الأمعاء أو تمزق الأمعاء (قد يسبب ألم المعدة، الحمى، الغثيان، القيء، انسداد الأمعاء)، براز داكن أو أسود اللون، التهاب البنكرياس (قد يسبب ألم المعدة)، التهاب المريء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم (حالة تعرف باسم نقص صوديوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (التي تساعد على حماية الجسم من العدوى) أو الصفيحات الدموية (مما يزيد من احتمالات النزيف أو التكدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة تنسيق حركات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتشوش، تغير مذاق الأشياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحساسية تجاه الضوء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهلاوس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حاد يمكن أن يؤدي إلى التهاب الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نظم القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوّن جلطات دموية في الأوعية الدموية في الرئتين. قد تتضمن الأعراض انقطاعًا مفاجئًا في النفس أو آلامًا حادة أثناء التنفس أو الانهيار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف المعدة أو الأمعاء (قد يتسبب في خروج دم مع البراز أو القيء)، التهاب الأمعاء أو القولون</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>التهاب شديد بالكبد. قد تتضمن الأعراض الغثيان، أو الإسهال، أو اليرقان (اصفرار الجلد أو العينين)، أو دكنة البول، أو برازًا ذا لون فاتح، أو سهولة النزيف، أو الحكة، أو القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى الحاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الطمث</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق، أو صعوبة البلع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا: قد </strong><strong>تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠٠ شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة (بما في ذلك صدمة تأقية يحتمل أن تكون مميتة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحالات الجلدية الخطيرة مثل متلازمة ستيفنز جونسون، والتهاب الجلد التقشري، وتقشر الأنسجة المتموتة البشروية التسممي (قد يسبب الطفح الجلدي، تبثر أو تقشر الجلد) والبثار الطفحي المعمم الحاد (تتضمن الأعراض احمرار الجلد مع وجود مناطق متورمة مغطاة بالعديد من البثور الصغيرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية متأخر مصحوب بأعراض محتملة مثل الطفح الجلدي، وتورم الوجه، والحمى، وتورم الغدد، ونتائج غير طبيعية للفحوصات (مثل فحوصات الكبد أو خلايا الدم (كثرة اليوزينيات، وهي إحدى حالات ارتفاع تعداد خلايا الدم البيضاء))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل الدماغ يسبب الوفاة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب السحايا (التهاب الأغشية المحيطة بالدماغ والحبل الشوكي)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>فشل الكبد وتضرر الكبد والتهاب شديد بالكبد (التهاب الكبد الخاطف) (أحيانًا ما قد يكون مميتًا أو يستلزم الخضوع لزرع كبد). قد تتضمن الأعراض الغثيان، أو الإسهال، أو اليرقان (اصفرار الجلد أو العينين)، أو دكنة البول، أو برازًا ذا لون فاتح، أو سهولة النزيف، أو الحكة، أو القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الكبد (مثل الركود الصفراوي، والتهاب الكبد الركودي الصفراوي، الذي قد يصاحبه أعراض مثل تلون البراز، والغثيان، واصفرار الجلد أو بياض العينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى ومشكلات أخرى بالكلى (مثل متلازمة أمراض الكلى ومرض التغير الطفيف، والذي قد يصاحبه أعراض مثل احتباس الماء (التورم)، والبول الرغوي، والإرهاق، وفقدان الشهية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور حالة الصرع (احتمال زيادة معدل النوبات و/أو زيادة شدتها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد أحد شرايين أو أوردة العين مما يؤدي إلى فقدان جزئي أو كلي للرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية (قد يسبب الحمى، الأوجاع، ظهور بقع أرجوانية على الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم الحمراء والبيضاء والصفيحات الدموية (قد يسبب التعب وسهولة التكدم ونزيف الأنف المتكرر وزيادة خطر الإصابة بالعدوى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات وضعفها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال حاسة الشم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة التذوق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير نسبة التكرار من البيانات المتاحة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الخصوبة في الإناث وعادة ما يكون قابل للعكس عند التوقف عن تناول الدواء</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>لوحظت الآثار الجانبية الإضافية التالية في دراسات سريرية غير مرتبطة بالتهاب المفاصل أو غيره من حالات التهاب المفاصل، تم فيها تناول سيليبريكس بجرعات بلغت ٤٠٠ ملجم في اليوم لما يصل إلى ٣ أعوام:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات قلبية: الذبحة الصدرية (ألم الصدر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات معدية: متلازمة تهيج القولون (قد تتضمن ألم المعدة، الإسهال، عسر الهضم، الغازات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصي الكلى (مما قد يسبب ألم المعدة أو الظهر، ظهور دم في البول)، صعوبة التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخثر الأوردة العميقة (جلطة دموية تتكون عادة في الساق قد تسبب الألم، أو تورم أو احمرار ربلة الساق، أو مشكلات في التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات معدية: عدوى المعدة (قد تسبب تهيج المعدة والأمعاء وتكوّن قرح بها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسور الأطراف السفلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهربس النطاقي، عدوى الجلد، الإكزيما (طفح جلدي جاف مثير للحكة)، التهاب الرئة (عدوى صدرية (مع احتمال الإصابة بالسعال، الحمى، صعوبة التنفس))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور أجسام طافية في العين تسبب اختلال أو تغيم الرؤية، الدوار نتيجة اضطرابات في الأذن الداخلية، تقرح أو التهاب أو نزيف اللثة، قرح الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كثرة التبول أثناء الليل، نزيف من البواسير، زيادة معدل التبرز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور كتل دهنية في الجلد أو مناطق أخرى، كيس عقدي (تورمات غير ضارة على المفاصل والأوتار أو حولها تصيب اليد أو القدم)، صعوبة الكلام، نزيف غير طبيعي أو شديد للغاية من المهبل، ألم الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الصوديوم في نتائج فحوصات الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الآثار الجانبية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><em>المملكة العربية السعودية:</em></strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ &nbsp;الدوائي</p><ul><li dir="RTL">&nbsp;</li><li dir="RTL">&nbsp;&nbsp;</li><li dir="RTL">الهاتف المجاني: ١٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/</li></ul><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><ul><li dir="RTL">دول الخليج الأخرى:</li></ul><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ سيليبريكس بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">لا تستخدم سيليبريكس بعد تاريخ انتهاء الصلاحية المدون على شريط البليستر والعبوة الكرتونية.&nbsp; يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">قم بتخزين سيليبريكس في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">تكون محتويات الكبسولة التي تم نثرها على مهروس التفاح أو عصيدة الأرز أو الزبادي مستقرة لمدة تصل إلى ٦ ساعات في البراد (الثلاجة) (من درجتين مئويتين إلى ٨ درجات مئوية).<strong> </strong>ينبغي ألا يتم تخزين محتويات الكبسولة التي تم رشها على الموز المهروس في البراد (الثلاجة).</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيليكوكسيب.</p><p dir="RTL">تحتوي الكبسولة الواحدة على ١٠٠ ملجم، أو ٢٠٠ ملجم، أو ٤٠٠ ملجم من سيليكوكسيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المكونات الأخرى هي:</u></p><p dir="RTL">لاكتوز أحادي الهيدرات، لوريل سلفات الصوديوم، بوليفيدون، كروسكارميلوز الصوديوم، ستيارات المغنيسيوم.</p><p dir="RTL">تحتوي قشرة الكبسولة على الجيلاتين، وثاني أكسيد التيتانيوم E171، ولوريل سلفات الصوديوم، وأحادي لورات السوربيتان.</p><p dir="RTL">يحتوي حبر الطباعة على أكسيد الحديد E172 لكبسولة الـ٢٠٠ ملجم، وصبغة ليك من الألومينيوم (E132) لكبسولة الـ١٠٠ ملجم، ويُستخدم كلا نوعي أكسيد الحديد E172 وصبغة ليك من الألومينيوم (E132) لكبسولة الـ٤٠٠ ملجم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر سيليبريكس في صورة كبسولات صلبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بيضاء غير شفافة تحمل شريطين باللون الأزرق موسومين بالرقمين ٧٧٦٧ و١٠٠ (سيليبريكس ١٠٠ ملجم).</p><p dir="RTL">بيضاء غير شفافة تحمل شريطين باللون الذهبي موسومين بالرقمين ٧٧٦٧ و٢٠٠ (سيليبريكس ٢٠٠ ملجم).</p><p dir="RTL">بيضاء غير شفافة تحمل شريطين باللون الأخضر موسومين بالرقمين ٧٧٦٧ و٤٠٠ (سيليبريكس ٤٠٠ ملجم).</p><p dir="RTL">تأتي الكبسولات معبأة في شرائط بليستر شفافة أو غير شفافة من كلوريد البولي فينيل/الألومنيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتم تعبئة كبسولات سيليبريكس ١٠٠ ملجم في عبوات تحتوي على ٢٠ كبسولة.</p><p dir="RTL">تتم تعبئة كبسولات سيليبريكس ٢٠٠ ملجم في عبوات تحتوي على ١٠ أو ٢٠ كبسولة.</p><p dir="RTL">تتم تعبئة كبسولات سيليبريكس ٤٠٠ ملجم في عبوات تحتوي على ١٠ كبسولات.</p><p dir="RTL"><em>&nbsp;</em></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سم وعنوان مالك رخصة التسويق والمصنع</strong></p><p dir="RTL">Pfizer Saudi Limited لكبسولات سيليبريكس ١٠٠ ملجم و٢٠٠ ملجم</p><p dir="RTL">Pfizer Inc.&ndash; الولايات المتحدة الأمريكية لكبسولات سيليبريكس ٤٠٠ ملجم</p><p dir="RTL">&nbsp;</p><p>الجهة المصنعة:</p><p dir="RTL"><strong>Pfizer Saudi Limited لكبسولات سيليبريكس&nbsp; ٢٠٠ ملجم</strong></p><p dir="RTL"><strong>&nbsp;Pfizer Pharmaceutical LLC, Vega Baja &ndash; PR- USA، الولايات المتحدة الأمريكية لكبسولات سيليبريكس١٠٠ملجم و ٤٠٠ ملجم</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Celebrex 100 mg hard capsules
Celebrex 200 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 100 mg capsule contains 100 mg celecoxib. 

Excipient with known effect 
Lactose (each capsule contains 149.7 mg lactose monohydrate; see section 4.4). 

Each 200 mg capsule contains 200 mg celecoxib.

Excipient with known effect 
Lactose (each capsule contains 49.8 mg lactose monohydrate; see section 4.4). 

For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules (capsule).
100 mg Capsules: Opaque, white capsules with two blue bands marked 7767 and 100.
200 mg Capsules: Opaque, white capsules with two gold bands marked 7767 and 200.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Celebrex is indicated in adults for the symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.</p><p><strong>Juvenile Idiopathic Arthritis (JIA)</strong></p><p>For the management of the signs and symptoms of JIA in patients 2 years and older,</p><p><strong>Acute Pain</strong></p><p>For the management of acute pain in adults,</p><p><strong>Primary Dysmenorrhea</strong></p><p>For the management of primary dysmenorrhea</p><p>The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3 and 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>As the cardiovascular (CV) risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).&nbsp;</p><p><em>&nbsp;</em></p><p><em>Osteoarthritis</em></p><p>The usual recommended daily dose is 200&nbsp;mg taken once daily or in two divided doses. In some patients, with insufficient relief from symptoms, an increased dose of 200&nbsp;mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p><em>&nbsp;</em></p><p><em>Rheumatoid </em><em>arthritis</em></p><p>The initial recommended daily dose is 200&nbsp;mg taken in two divided doses. The dose may, if needed, later be increased to 200&nbsp;mg twice daily. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p>&nbsp;</p><p><em>Ankylosing spondylitis</em></p><p>The recommended daily dose is 200&nbsp;mg taken once daily or in two divided doses. In a few patients, with insufficient relief from symptoms, an increased dose of 400&nbsp;mg once daily or in two divided doses may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p>&nbsp;</p><p><em>Juvenile Idiopathic Arthritis</em></p><p>For JIA, the dosage for pediatric patients (age 2 years and older) is based on weight. For patients &gt;10 kg to &lt;25 kg the recommended dose is 50 mg twice daily. For patients &gt;25 kg the recommended dose is 100 mg twice daily.</p><p>For patients who have difficulty swallowing capsules, the contents of a CELEBREX capsule can be added to applesauce. The entire capsule contents are carefully emptied onto a level teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled capsule contents on applesauce are stable for up to 6 hours under refrigerated conditions (2&deg; C to 8&deg; C).</p><p>&nbsp;</p><p><em>Management of Acute Pain and Treatment of Primary Dysmenorrhea</em></p><p>For management of Acute Pain and Treatment of Primary Dysmenorrhea, the dosage is 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily as needed.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Elderly</em></p><p>As in younger adults, 200&nbsp;mg per day should be used initially. The dose may, if needed, later be increased to 200&nbsp;mg twice daily. Particular caution should be exercised in elderly with a body weight less than 50&nbsp;kg (see sections 4.4 and 5.2).</p><p><em>CYP2C9 poor metabolisers</em></p><p>Patients who are known, or suspected to be CYP2C9 poor metabolisers based on genotyping or previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution as the risk of dose-dependent adverse effects is increased. Consider reducing the dose to half the lowest recommended dose<sup> </sup>(see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Treatment should be initiated at half the recommended dose<strong><em> </em></strong>in patients with established<strong><em> </em></strong>moderate liver impairment with a serum<strong><em> </em></strong>albumin of<strong><em> </em></strong>25-35&nbsp;g/l. Experience in such patients is limited to cirrhotic patients (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p><em>Oral use</em></p><p>Celebrex may be taken with or without food. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce, rice gruel, yogurt or mashed banana. To do so, the entire capsule contents must be carefully emptied onto a level teaspoon of cool or room temperature applesauce, rice gruel, yogurt or mashed banana and should be ingested immediately with 240&nbsp;ml of water. The sprinkled capsule contents on applesauce, rice gruel or yogurt are stable for up to 6&nbsp;hours under refrigerated conditions (2‑8 &deg;C).<strong> </strong>The sprinkled capsule contents on mashed banana should not be stored under refrigerated conditions and should be ingested immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known hypersensitivity to sulfonamides.

Active peptic ulceration or gastrointestinal (GI) bleeding.

Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid (aspirin) or other non steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.

In pregnancy and in women of childbearing potential unless using an effective method of contraception (see section 4.6). Celecoxib has been shown to cause malformations in the two animal species studied (see sections 4.6 and 5.3). The potential for human risk in pregnancy is unknown but cannot be excluded.

Breast-feeding (see sections 4.6 and 5.3).

Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score 10).

Patients with estimated creatinine clearance <30 ml/min.

Inflammatory bowel disease.

Congestive heart failure (NYHA II-IV).

Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastrointestinal (GI) effects</u></p><p>Upper and lower gastrointestinal complications (perforations, ulcers or bleedings [PUBs]), some of them resulting in fatal outcome, have occurred in patients treated with celecoxib. Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or antiplatelet drugs (such as acetylsalicylic acid) or glucocorticoids concomitantly, patients using alcohol, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p>&nbsp;</p><p>There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).&nbsp;</p><p>&nbsp;</p><p>A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid vs. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).</p><p>&nbsp;</p><p><u>Concomitant NSAID use</u></p><p>The concomitant use of celecoxib and a non-aspirin NSAID should be avoided.</p><p>&nbsp;</p><p><u>Cardiovascular effects</u></p><p>Increased number of serious cardiovascular (CV) events, mainly myocardial infarction, has been found in a long-term placebo-controlled study in subjects with sporadic adenomatous polyps treated with celecoxib at doses of 200&nbsp;mg bis in die (BID) and 400&nbsp;mg BID compared to placebo (see section 5.1).</p><p>&nbsp;</p><p>As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. NSAIDs, including COX-2 selective inhibitors, have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long-term. The exact magnitude of the risk associated with a single-dose has not been determined, nor has the exact duration of therapy associated with increased risk. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).</p><p>&nbsp;</p><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see section 5.1).</p><p>&nbsp;</p><p>COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects.&nbsp; Therefore, antiplatelet therapies should not be discontinued (see section 5.1).</p><p>&nbsp;</p><p><u>Fluid retention and oedema</u></p><p>As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention and oedema have been observed in patients taking celecoxib. Therefore, celecoxib should be used with caution in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention. Caution is also required in patients taking diuretic treatment or otherwise at risk of hypovolaemia.</p><p>&nbsp;</p><p><u>Hypertension</u></p><p>As with all NSAIDS, celecoxib can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. Therefore, blood pressure should be monitored closely during the initiation of therapy with celecoxib and throughout the course of therapy.</p><p>&nbsp;</p><p><u>Hepatic and renal effects</u></p><p>Compromised renal or hepatic function and especially cardiac dysfunction are more likely in the elderly and therefore medically appropriate supervision should be maintained.</p><p>&nbsp;</p><p>NSAIDs, including celecoxib, may cause renal toxicity.<sup> </sup>Clinical trials with celecoxib have shown renal effects similar to those observed with comparator NSAIDs. Patients at greatest risk for renal toxicity are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, angiotensin converting enzyme (ACE)-inhibitors, angiotensin II receptor antagonists, and the elderly (see section 4.5).&nbsp;Such patients should be carefully monitored while receiving treatment with celecoxib.<sup> </sup></p><p>&nbsp;</p><p>Some cases of severe hepatic reactions, including fulminant hepatitis (some with fatal outcome), liver necrosis and, hepatic failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. Among the cases that reported time to onset, most of the severe adverse hepatic events developed within one month after initiation of celecoxib treatment (see section 4.8).</p><p>&nbsp;</p><p>If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of celecoxib therapy should be considered.</p><p>&nbsp;</p><p><u>CYP2D6 inhibition</u></p><p>Celecoxib inhibits CYP2D6. Although it is not a strong inhibitor of this enzyme, a dose reduction may be necessary for individually dose-titrated medicinal products that are metabolised by CYP2D6 (see section 4.5).</p><p>&nbsp;</p><p><u>CYP2C9 poor metabolisers</u></p><p>Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).</p><p>&nbsp;</p><p><u>Skin and systemic hypersensitivity reactions</u></p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of celecoxib (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (including anaphylaxis, angioedema and drug rash with eosinophilia and systemic symptoms (DRESS), or hypersensitivity syndrome), have been reported in patients receiving celecoxib (see section 4.8). Patients with a history of sulfonamide allergy or any drug allergy may be at greater risk of serious skin reactions or hypersensitivity reactions (see section 4.3). Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>&nbsp;</p><p><u>Premature closure of the ductus arteriosus</u></p><p>Celecoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause premature closure of the ductus arteriosus during the last trimester (see section 4.6)</p><p>&nbsp;</p><p><u>General</u></p><p>Celecoxib may mask fever and other signs of inflammation.</p><p>&nbsp;</p><p><u>Use with oral anticoagulants</u></p><p>In patients on concurrent therapy with warfarin, serious bleeding events, some of them fatal, have been reported. Increased prothrombin time (INR) with concurrent therapy has been reported. Therefore, this should be closely monitored in patients receiving warfarin/coumarin‑type oral anticoagulants, particularly when therapy with celecoxib is initiated or celecoxib dose is changed (see section 4.5). Concomitant use of anticoagulants with NSAIDS may increase the risk of bleeding. Caution should be exercised when combining celecoxib with warfarin or other oral anticoagulants, including novel anticoagulants (e.g. apixaban, dabigatran, and rivaroxaban).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Celebrex 100&nbsp;mg and 200&nbsp;mg capsules contain lactose (149.7&nbsp;mg and 49.8&nbsp;mg, respectively). Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>Celebrex 100&nbsp;mg and 200&nbsp;mg contains less than 1 mmol sodium (23&nbsp;mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u></p><p>&nbsp;</p><p><em>Anticoagulants</em></p><p>Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of celecoxib in patients receiving warfarin or other anticoagulants since these patients have an increased risk of bleeding complications. Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with celecoxib is initiated or the dose of celecoxib is changed (see section 4.4).&nbsp; Bleeding events in association with increases in prothrombin time have been reported, predominantly in the elderly, in patients receiving celecoxib concurrently with warfarin, some of them fatal.</p><p>&nbsp;</p><p><em>Anti-hypertensives</em></p><p>NSAIDs may reduce the effect of anti-hypertensive medicinal products including ACE‑inhibitors, angiotensin II receptor antagonists,<strong> </strong>diuretics and beta-blockers. As for NSAIDs, the risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function (e.g. dehydrated patients, patients on diuretics, or elderly patients) when ACE-inhibitors, angiotensin II receptor antagonists, and/or diuretics are combined with NSAIDs, including celecoxib (see section 4.4). Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>&nbsp;</p><p>In a 28-day clinical study in patients with lisinopril-controlled Stage I and II hypertension, administration of celecoxib 200 mg&nbsp;BID resulted in no clinically significant increases, when compared to placebo treatment, in mean daily systolic or diastolic blood pressure as determined using 24-hour ambulatory blood pressure monitoring.&nbsp; Among patients treated with celecoxib 200&nbsp;mg&nbsp;BID, 48 %&nbsp;were considered unresponsive to lisinopril at the final clinic visit (defined as either cuff diastolic blood pressure &gt;90&nbsp;mmHg or cuff diastolic blood pressure increased &gt;10 % compared to baseline), compared to 27 %&nbsp;of patients treated with placebo; this difference was statistically significant.</p><p>&nbsp;</p><p><em>Ciclosporin and tacrolimus</em></p><p>Co-administration of NSAIDs and ciclosporin or tacrolimus may increase the nephrotoxic effect of ciclosporin or tacrolimus, respectively. Renal function should be monitored when celecoxib and any of these medicinal products are combined.</p><p>&nbsp;</p><p><em>Acetylsalicylic acid</em></p><p>Celecoxib can be used with low-dose acetylsalicylic acid but is not a substitute for acetylsalicylic acid for CV prophylaxis. In the submitted studies, as with other NSAIDs, an increased risk of gastrointestinal ulceration or other gastrointestinal complications compared to use of celecoxib alone was shown for concomitant administration of low-dose acetylsalicylic acid (see section 5.1).</p><p><em>&nbsp;</em></p><p><u>Pharmacokinetic interactions</u></p><p><em>&nbsp;</em></p><p><em>Effects of celecoxib on other medicinal products</em></p><p>&nbsp;</p><p><em><u>CYP2D6 inhibition</u></em></p><p>Celecoxib is an inhibitor of CYP2D6. The plasma concentrations of medicinal products that are substrates of this enzyme may be increased when celecoxib is used concomitantly. Examples of medicinal products which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs), neuroleptics, anti-arrhythmic medicinal products, etc. The dose of individually dose-titrated CYP2D6 substrates may need to be reduced when treatment with celecoxib is initiated or increased if treatment with celecoxib is terminated.</p><p>&nbsp;</p><p>Concomitant administration of celecoxib 200&nbsp;mg twice daily resulted in 2.6-fold and 1.5-fold increases in plasma concentrations of dextromethorphan and metoprolol (CYP2D6 substrates), respectively. These increases are due to celecoxib inhibition of the CYP2D6 substrate metabolism.</p><p><em>&nbsp;</em></p><p><em><u>CYP2C19 inhibition</u></em></p><p><em>In vitro</em> studies have shown some potential for celecoxib to inhibit CYP2C19 catalysed metabolism. The clinical significance of this <em>in vitro</em> finding is unknown. Examples of medicinal products which are metabolised by CYP2C19 are diazepam, citalopram and imipramine.</p><p>&nbsp;</p><p><em><u>Methotrexate</u></em><u> </u></p><p>In patients with rheumatoid arthritis celecoxib had no statistically significant effect on the pharmacokinetics (plasma or renal clearance) of methotrexate (in rheumatologic doses).&nbsp; However, adequate monitoring for methotrexate-related toxicity should be considered when combining these two medicinal products.</p><p>&nbsp;</p><p><em><u>Lithium</u></em></p><p>In healthy subjects, co-administration of celecoxib 200&nbsp;mg twice daily with 450&nbsp;mg twice daily of lithium resulted in a mean increase in C<sub>max </sub>of 16 % and in area under the curve (AUC) of 18 % of lithium. Therefore, patients on lithium treatment should be closely monitored when celecoxib is introduced or withdrawn.</p><p>&nbsp;</p><p><em><u>Oral contraceptives</u></em></p><p>In an interaction study, celecoxib had no clinically relevant effects on the pharmacokinetics of oral contraceptives (1&nbsp;mg norethisterone /35&nbsp;micrograms ethinylestradiol).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Glibenclamide/tolbutamide</u></em></p><p>Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide<strong><em> </em></strong>to a clinically relevant extent.</p><p><em>&nbsp;</em></p><p><em>Effects of other medicinal products on celecoxib</em></p><p>&nbsp;</p><p><em><u>CYP2C9 poor metabolisers</u></em></p><p>In individuals who are CYP2C9 poor metabolisers and demonstrate increased systemic exposure to celecoxib, concomitant treatment with CYP2C9 inhibitors such as fluconazole could result in further increases in celecoxib exposure. Such combinations should be avoided in known CYP2C9 poor metabolisers (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><em><u>CYP2C9 inhibitors and inducers</u></em></p><p>Since celecoxib is predominantly metabolised by CYP2C9 it should be used at half the recommended dose in patients receiving fluconazole. Concomitant use of 200 mg single-dose of celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib C<sub>max </sub>of 60% and in AUC of 130%. Concomitant use of inducers of CYP2C9 such as rifampicin, carbamazepine and barbiturates may reduce plasma concentrations of celecoxib.</p><p>&nbsp;</p><p><em><u>Ketoconazole and antacids</u></em></p><p>Ketoconazole or antacids have not been observed to affect the pharmacokinetics of celecoxib.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see sections 4.3 and 5.3). Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy. The potential for human risk in pregnancy is unknown, but cannot be excluded. Celecoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.</p><p>&nbsp;</p><p>During the second or third trimester of pregnancy, NSAIDs including celecoxib may cause fetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. Such effects may occur shortly after treatment initiation and are usually reversible upon discontinuation.</p><p>&nbsp;</p><p>If a woman becomes pregnant during treatment, celecoxib should be discontinued.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma. Administration of celecoxib to a limited number of lactating women has shown a very low transfer of celecoxib into breast milk. Women who take Celebrex should not breastfeed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Based on the mechanism of action, the use of NSAIDs, including celecoxib, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Celebrex may have minor influence on the ability to drive and use machines. Patients who experience dizziness, vertigo or somnolence while taking Celebrex should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed by system organ class and ranked by frequency in <strong>Table 1</strong>, reflecting data from the following sources:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported in osteoarthritis patients and rheumatoid arthritis patients at incidence rates greater than 0.01 % and greater than those reported for placebo during 12&nbsp;placebo- and/or active-controlled clinical trials of duration up to 12 weeks at celecoxib daily doses from 100&nbsp;mg up to 800&nbsp;mg.&nbsp; In additional studies using non-selective NSAID comparators, approximately 7 400&nbsp;arthritis patients have been treated with celecoxib at daily doses up to 800&nbsp;mg, including approximately 2 300&nbsp;patients treated for 1&nbsp;year or longer.&nbsp; The adverse reactions observed with celecoxib in these additional studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in <strong>Table 1</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported at incidence rates greater than placebo for subjects treated with celecoxib 400&nbsp;mg daily in long-term polyp prevention trials of duration up to 3&nbsp;years (the Adenoma Prevention with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials; see&nbsp;section&nbsp;5.1, Cardiovascular safety&nbsp;&ndash;&nbsp;long‑term studies involving patients with sporadic adenomatous polyps).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated &gt;70&nbsp;million patients were treated with celecoxib (various doses, durations, and indications).&nbsp; Even though these were identified as reactions from post-marketing reports, trial data was consulted to estimate frequency. Frequencies are based on a cumulative meta-analysis with pooling of trials representing exposure in 38102&nbsp;patients.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>1. Adverse drug reactions in celecoxib clinical trials and surveillance experience (MedDRA preferred terms)<sup>1,2</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Adverse Drug Reaction Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p>(&ge; 1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge; 1/100 to &lt; 1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge; 1/1,000 to &lt; 1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge; 1/10,000 to &lt; 1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p>(&lt; 1/10,000)</p></td><td style="vertical-align:top"><p><strong>Not known </strong></p><p><strong>(cannot be estimated from available data)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sinusitis, upper respiratory tract infection, pharyngitis,urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Leukopenia, thrombo-cytopenia</p></td><td style="vertical-align:top"><p>Pancytopenia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyper-sensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock<sup>4</sup>, anaphylactic reaction<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, depression, fatigue</p></td><td style="vertical-align:top"><p>Confusional state, hallucinations<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness, hypertonia, headache<sup>4</sup></p></td><td style="vertical-align:top"><p>Cerebral infarction<sup>1</sup>, paraesthesia, somnolence</p></td><td style="vertical-align:top"><p>Ataxia, dysgeusia</p></td><td style="vertical-align:top"><p>Haemorrhage intracranial (including fatal intracranial haemorrhage)<sup>4</sup>, meningitis aseptic<sup>4</sup>, epilepsy (including aggravated epilepsy)<sup>4</sup>, ageusia<sup>4</sup>, anosmia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision blurred, conjunctivitis<sup>4</sup></p></td><td style="vertical-align:top"><p>Eye haemorrhage<sup>4</sup></p></td><td style="vertical-align:top"><p>Retinal artery occlusion<sup>4</sup>, retinal vein occlusion<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus, hypoacusis<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction<sup>1</sup></p></td><td style="vertical-align:top"><p>Cardiac failure, palpitations, tachycardia</p></td><td style="vertical-align:top"><p>Arrhythmia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Hyper-tension<sup>1 </sup>(including aggravated hyper-tension)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism<sup>4</sup>, flushing<sup>4</sup></p></td><td style="vertical-align:top"><p>Vasculitis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic, and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhinitis, cough, dyspnoea<sup>1</sup></p></td><td style="vertical-align:top"><p>Bronchospasm<sup>4</sup></p></td><td style="vertical-align:top"><p>Pneumonitis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea<sup>4</sup>, abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting<sup>1</sup>, <sup>&nbsp;</sup>dysphagia<sup>1</sup></p></td><td style="vertical-align:top"><p>Constipation, gastritis, stomatitis, gastrointestinal inflammation (including aggravation of gastrointestinal inflammation), eructation</p></td><td style="vertical-align:top"><p>Gastro-intestinal haemorrhage<sup>4</sup>, duodenal ulcer, gastric ulcer, oesophageal ulcer, intestinal ulcer, large intestinal ulcer, intestinal perforation, oesophagitis, melaena, pancreatitis, colitis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic function abnormal, hepatic enzyme increased (including increased SGOT and SGPT)</p></td><td style="vertical-align:top"><p>Hepatitis<sup>4</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic failure<sup>4</sup> (sometimes fatal or requiring liver transplant), hepatitis fulminant<sup>4</sup> (some with fatal outcome), hepatic necrosis<sup>4</sup>, cholestasis<sup>4</sup>, hepatitis cholestatic<sup>4</sup>, jaundice<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, pruritus (includes pruritus generalised)</p></td><td style="vertical-align:top"><p>Urticaria, ecchymosis<sup>4</sup></p></td><td style="vertical-align:top"><p>Angioedema<sup>4</sup>, alopecia, photo-sensitivity</p></td><td style="vertical-align:top"><p>Dermatitis exfoliative<sup>4</sup>, erythema multiforme<sup>4</sup>, Stevens-Johnson syndrome<sup>4</sup>, toxic epidermal necrolysis<sup>4</sup>, drug reaction with eosinophilia and systemic symptoms (DRESS)<sup> 4</sup>, acute generalised exanthematous pustulosis (AGEP)<sup>4</sup>, dermatitis bullous<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia<sup>4</sup></p></td><td style="vertical-align:top"><p>Muscle spasms (leg cramps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myositis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased, blood urea increased</p></td><td style="vertical-align:top"><p>Renal failure acute<sup>4</sup>, hypo-natraemia<sup>4</sup></p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis<sup>4</sup>, nephrotic syndrome<sup>4</sup>, glomerulonephritis minimal lesion<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Menstrual disorder<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infertility female (female fertility decreased)<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influenza-like illness, oedema peripheral/ fluid retention</p></td><td style="vertical-align:top"><p>Face oedema, chest pain<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injury (accidental injury)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td><td colspan="6" style="vertical-align:top"><p>SGOT - serum glutamic oxaloacetic transaminase</p><p>SGPT - serum glutamic pyruvic transaminase</p><p><sup>1 </sup>Adverse drug reactions that occurred in polyp prevention trials, representing subjects treated with celecoxib 400&nbsp;mg daily in 2&nbsp;clinical trials of duration up to 3&nbsp;years (the APC and PreSAP trials).&nbsp; The adverse drug reactions listed above for the polyp prevention trials are only those that have been previously recognised in the post-marketing surveillance experience, or have occurred more frequently than in the arthritis trials.</p><p><sup>2 </sup>Furthermore, the following <em>previously unknown</em> adverse reactions occurred in polyp prevention trials, representing subjects treated with celecoxib 400&nbsp;mg daily in 2&nbsp;clinical trials of duration up to 3&nbsp;years (the APC and PreSAP trials):</p><p><strong>Common:</strong> angina pectoris, irritable bowel syndrome, nephrolithiasis, blood creatinine increased, benign prostatic hyperplasia, weight increased. <strong>Uncommon: </strong>helicobacter infection, herpes zoster, erysipelas, bronchopneumonia, labyrinthitis, gingival infection, lipoma, vitreous floaters, conjunctival haemorrhage, deep vein thrombosis, dysphonia, haemorrhoidal haemorrhage, frequent bowel movements, mouth ulceration, allergic dermatitis, ganglion, nocturia, vaginal haemorrhage, breast tenderness, lower limb fracture, blood sodium increased.</p><p><sup>3 </sup>Women intending to become pregnant are excluded from all trials, thus consultation of the trial database for the frequency of this event was not reasonable.</p><p><sup>4 </sup>Frequencies are based on cumulative meta-analysis with pooling of trials representing exposure in 38102 patients.</p></td></tr></tbody></table><p>&nbsp;</p><p>In final data (adjudicated) from the APC and PreSAP trials in patients treated with celecoxib 400&nbsp;mg daily for up to 3&nbsp;years (pooled data from both trials; see section&nbsp;5.1 for results from individual trials), the excess rate over placebo for myocardial infarction was 7.6&nbsp;events per 1,000&nbsp;patients (uncommon) and there was no excess rate for stroke (types not differentiated) over placebo.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local requirements. </u></p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>Please contact the relevant competent authority.</li></ul></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience of overdose. Single-doses up to 1200&nbsp;mg and multiple doses up to 1200 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse effects. In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment. Dialysis is unlikely to be an efficient method of medicinal product removal due to high protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Non-steroidal anti-inflammatory and antirheumatic drugs, NSAIDs, Coxibs, ATC code: M01AH01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Celecoxib is an oral, selective, COX-2 inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as <em>ex vivo</em> inhibition of thromboxane B<sub>2</sub> [TxB<sub>2</sub>] formation) was observed in this dose range in healthy volunteers.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in humans but its relevance to ulcer healing has not been established.</p><p>&nbsp;</p><p>The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.</p><p>&nbsp;</p><p>Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxizole and other sulfonamide antibiotics).</p><p>&nbsp;</p><p>A dose-dependent effect on TxB<sub>2 </sub>formation has been observed after high doses of celecoxib. However, in healthy subjects, in small multiple dose studies with 600 mg BID (three times the highest recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Several clinical studies have been performed confirming efficacy and safety in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the inflammation and pain of osteoarthritis of the knee and hip in approximately 4200 patients in placebo and active-controlled trials of up to 12 weeks duration.&nbsp; It was also evaluated for treatment of the inflammation and pain of rheumatoid arthritis in approximately 2100 patients in placebo and active-controlled trials of up to 24 weeks duration.&nbsp; Celecoxib at daily doses of 200&nbsp;mg &ndash; 400&nbsp;mg provided pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of ankylosing spondylitis in 896 patients in placebo and active-controlled trials of up to 12 weeks duration.&nbsp; Celecoxib at doses of 100&nbsp;mg BID, 200&nbsp;mg QD, 200&nbsp;mg BID and 400&nbsp;mg QD in these studies demonstrated significant improvement in pain, global disease activity and function in ankylosing spondylitis.</p><p>&nbsp;</p><p>Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4500 patients free from initial ulceration (celecoxib doses from 50&nbsp;mg &ndash; 400&nbsp;mg BID). In twelve week endoscopy studies celecoxib (100 &ndash; 800&nbsp;mg per day) was associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1000&nbsp;mg per day) and ibuprofen (2400&nbsp;mg per day). The data were inconsistent in comparison with diclofenac (150&nbsp;mg per day). In two of the 12-week studies the percentage of patients with endoscopic gastroduodenal ulceration was not significantly different between placebo and celecoxib 200&nbsp;mg BID and 400&nbsp;mg BID.&nbsp;</p><p>&nbsp;</p><p>In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study), 5,800 osteoarthritis and 2,200 rheumatoid arthritis patients received celecoxib 400&nbsp;mg BID (4-fold and 2-fold the recommended osteoarthritis and rheumatoid arthritis doses, respectively), ibuprofen 800&nbsp;mg ter in die (TID) or diclofenac 75 mg BID (both at therapeutic doses). Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (&le;325&nbsp;mg/day), primarily for cardiovascular (CV) prophylaxis. For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually. Also for the combined NSAID group there was no statistically significant difference for complicated ulcers (relative risk 0.77, 95 % CI 0.41-1.46, based on entire study duration). For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib group compared to the NSAID group, relative risk 0.66, 95 % CI 0.45-0.97 but not between celecoxib and diclofenac. Those patients on celecoxib and concomitant low-dose acetylsalicylic acid experienced 4-fold higher rates of complicated ulcers as compared to those on celecoxib alone. The incidence of clinically significant decreases in haemoglobin (&gt;2 g/dL), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95 % CI 0.17- 0.48. The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.</p><p>&nbsp;</p><p>In a prospective randomised 24 week safety study in patients who were aged &ge;60 years or had a&nbsp; history of gastroduodenal ulcers [users of acetylsalicylic acid (ASA) excluded], the percentages of patients with decreases in haemoglobin (&ge;2 g/dL) and/or haematocrit (&ge;10 %) of defined or presumed GI origin were lower in patients treated with celecoxib 200 mg twice daily (N=2238) compared to patients treated with diclofenac SR 75 mg twice daily plus omeprazole 20 mg once daily (N=2246) (0.2 % vs. 1.1 % for defined GI origin, p = 0.004; 0.4 % vs. 2.4 % for presumed GI origin, p = 0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or haemorrhage were very low with no differences between the treatment groups (4-5 per group).</p><p>&nbsp;</p><p><u>Cardiovascular safety &ndash; long-term studies involving subjects with sporadic adenomatous polyps</u></p><p>Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial and the PreSAP trial.&nbsp; In the APC trial, there was a dose-related increase in the composite endpoint of CV death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to placebo over 3&nbsp;years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.</p><p>&nbsp;</p><p>In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of CV death, myocardial infarction, or stroke were 3.4&nbsp;(95 %&nbsp;CI 1.4 - 8.5) with celecoxib 400&nbsp;mg twice daily and 2.8&nbsp;(95 % CI 1.1&nbsp;‑ 7.2) with celecoxib 200&nbsp;mg&nbsp;twice daily. Cumulative rates for this composite endpoint over 3&nbsp;years were 3.0 % (20/671 subjects) and 2.5 % (17/685 subjects), respectively, compared to 0.9 % (6/679 subjects) for placebo.&nbsp; The increases for both celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction.</p><p>&nbsp;</p><p>In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2&nbsp;(95 % CI 0.6 ‑ 2.4) with celecoxib 400&nbsp;mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3&nbsp;years were 2.3 % (21/933 subjects) and 1.9 % (12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was 1.0 % (9/933 subjects) with celecoxib 400 mg once daily and 0.6 % (4/628 subjects) with placebo.</p><p>&nbsp;</p><p>Data from a third long-term study, ADAPT (The Alzheimer&#39;s Disease Anti-inflammatory Prevention Trial), did not show a significantly increased CV risk with celecoxib 200&nbsp;mg BID compared to placebo. The relative risk compared to placebo for a similar composite endpoint (CV death, myocardial infarction, stroke) was 1.14&nbsp;(95 % CI 0.61 ‑ 2.15) with celecoxib 200&nbsp;mg twice daily. The incidence of myocardial infarction was 1.1 % (8/717 patients) with celecoxib 200 mg twice daily and 1.2 % (13/1070 patients) with placebo.</p><p>&nbsp;</p><p><strong>Juvenile Idiopathic Arthritis </strong></p><p>In a 12-week, randomized, double-blind active-controlled, parallel-group, multicenter, non-inferiority study, patients from 2&nbsp;years to 17 years of age with pauciarticular, polyarticular course JIA or systemic onset JIA (with currently inactive systemic features), received one of the following treatments: celecoxib 3 mg/kg (to a maximum of 150 mg) twice daily; celecoxib 6 mg/kg (to a maximum of 300 mg) twice daily; or naproxen 7.5&nbsp;mg/kg (to a maximum of 500 mg) twice daily. The response rates were based upon the JIA Definition of Improvement greater than or equal to 30% (JIA DOI 30) criterion, which is a composite of clinical, laboratory, and functional measures of JIA. The JIA DOI 30 response rates at week 12 were 69%, 80% and 67% in the celecoxib 3 mg/kg twice daily, celecoxib 6 mg/kg twice daily, and naproxen 7.5 mg/kg twice daily treatment groups, respectively.</p><p>&nbsp;</p><p>The efficacy and safety of Celebrex for JIA have not been studied beyond six months. The long-term cardiovascular toxicity in children exposed to Celebrex has not been evaluated and it is unknown if the long-term risk may be similar to that seen in adults exposed to Celebrex or other COX-2 selective and non-selective NSAIDs</p><p>&nbsp;</p><p><strong>Analgesia, including Primary Dysmenorrhea </strong></p><p>In acute analgesic models of post-oral surgery pain, post‑orthopedic surgical pain, and primary dysmenorrhea, Celebrex relieved pain that was rated by patients as moderate to severe. Single doses of Celebrex provided pain relief within 60&nbsp;minutes.</p><p><u>Prospective randomised evaluation of celecoxib integrated safety vs. ibuprofen or naproxen (PRECISION)</u></p><p>The PRECISION study was a double-blind study of cardiovascular safety in Osteo arthritis (OA) or Rheumatoid arthritis (RA) patients with or at high risk for cardiovascular disease comparing Celecoxib (200-400 mg daily) with Naproxen (750-1 000 mg daily) and Ibuprofen (1 800-2 400 mg daily). The primary endpoint, Antiplatelet Trialists Collaboration (APTC), was an independently adjudicated composite of cardiovascular death (including haemorrhagic death), non-fatal myocardial infarction or non-fatal stroke. The study was planned with 80% power to evaluate non‑inferiority. All patients were prescribed open-label esomeprazole (20-40 mg) for gastro protection. Patients who were taking low-dose aspirin were permitted to continue therapy, at baseline nearly half of the subjects were on aspirin.&nbsp; Secondary and tertiary endpoints included cardiovascular, gastrointestinal and renal outcomes. The Average Dose dispensed was 209&plusmn;37 mg/day for Celecoxib, 2045&plusmn;246 for Ibuprofen and 852&plusmn;103 for Naproxen<strong>.</strong></p><p>Regarding the primary endpoint, Celecoxib, as compared with either naproxen or ibuprofen, met all four pre-specified non-inferiority requirements, see Table 2.</p><p>&nbsp;</p><p>Other independently adjudicated secondary and tertiary endpoints included cardiovascular, gastrointestinal and renal outcomes. Additionally, there was a 4-month substudy focusing on the effects of the three medicinal products on blood pressure as measured by ambulatory monitoring (ABPM).</p><p>&nbsp;</p><p><strong>Table 2. Primary analysis of the adjudicated APTC composite endpoint</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Intent-To-Treat Analysis (ITT, through month 30) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Celecoxib 100-200 mg bid</strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen 600-800 mg tid</strong></p></td><td style="vertical-align:top"><p><strong>Naproxen 375-500 mg bid</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>8,072</p></td><td style="vertical-align:top"><p>8,040</p></td><td style="vertical-align:top"><p>7,969</p></td></tr><tr><td style="vertical-align:top"><p>Subjects with Events</p></td><td style="vertical-align:top"><p>188 (2.3%)</p></td><td style="vertical-align:top"><p>218 (2.7%)</p></td><td style="vertical-align:top"><p>201 (2.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Pairwise Comparison</p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. Naproxen</strong></p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. Ibuprofen </strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen vs. Naproxen </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; HR (95% CI)</p></td><td style="vertical-align:top"><p>0.93 (0.76, 1.13)</p></td><td style="vertical-align:top"><p>0.86 (0.70, 1.04)</p></td><td style="vertical-align:top"><p>1.08 (0.89, 1.31)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Modified Intent-To-Treat Analysis (mITT, on treatment through month 43)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Celecoxib 100-200 mg bid</strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen 600-800 mg tid</strong></p></td><td style="vertical-align:top"><p><strong>Naproxen 375-500 mg bid</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>8,030</p></td><td style="vertical-align:top"><p>7,990</p></td><td style="vertical-align:top"><p>7,933</p></td></tr><tr><td style="vertical-align:top"><p>Subjects with Events</p></td><td style="vertical-align:top"><p>134 (1.7%)</p></td><td style="vertical-align:top"><p>155 (1.9%)</p></td><td style="vertical-align:top"><p>144 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Pairwise Comparison</p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. Naproxen</strong></p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. Ibuprofen </strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen vs. Naproxen </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; HR (95% CI)</p></td><td style="vertical-align:top"><p>0.90 (0.72, 1.14)</p></td><td style="vertical-align:top"><p>0.81 (0.64, 1.02)</p></td><td style="vertical-align:top"><p>1.12 (0.889, 1.40)</p></td></tr></tbody></table><p>HR - hazard Ratio</p><p>BID - bis in die</p><p>TID - ter in die</p><p>&nbsp;</p><p>The results were overall numerically similar in the celecoxib and comparator groups for the secondary and tertiary endpoints and there were overall no unexpected safety findings.</p><p>&nbsp;</p><p>Taken together the PRECISION study indicates that celecoxib at the lowest approved dose of 100 mg twice daily is non-inferior to ibuprofen dosed in the range of 600 mg-800 mg three times daily or naproxen dosed in the range of 375 mg-500 mg twice daily with respect to cardiovascular adverse effects. The cardiovascular risks of the NSAID class, including coxibs, are dose-dependent, therefore, the results for celecoxib 200 mg daily on the composite cardiovascular endpoint cannot be extrapolated to dosing regimens using the higher doses of celecoxib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours. Dosing with food (high fat meal) delays absorption of celecoxib by about 1 hour resulting in a T<sub>max</sub> of about 4 hours and increases bioavailability by about 20%.</p><p>&nbsp;</p><p>In healthy adult volunteers, the overall systemic exposure (AUC) of celecoxib was equivalent when celecoxib was administered as intact capsule or capsule contents sprinkled on applesauce. There were no significant alterations in C<sub>max</sub>, T<sub>max</sub> or T<sub>1/2</sub> after administration of capsule contents on applesauce.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Plasma protein binding is about 97&nbsp;% at therapeutic plasma concentrations and the medicinal product is not preferentially bound to erythrocytes.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, inactive as COX-1 or COX-2 inhibitors, have been identified in human plasma i.e., a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate.<br /><br />Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.</p><p>&nbsp;</p><p>In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median C<sub>max</sub> and AUC<sub>0-24</sub> of celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes. In three separate single-dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/*3, single-dose AUC<sub>0-24</sub> increased by approximately 3-fold compared to normal metabolisers.&nbsp; It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3-1.0 % among different ethnic groups.&nbsp;</p><p>&nbsp;</p><p>Patients who are known, or suspected to be CYP2C9 poor metabolisers based on previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution (see section 4.2).</p><p>&nbsp;</p><p>No clinically significant differences were found in Pharmacokinetic parameters of celecoxib between elderly African-Americans and Caucasians.</p><p>&nbsp;</p><p>The plasma concentration of celecoxib is approximately 100 % increased in elderly women (&gt;65 years).</p><p>&nbsp;</p><p>Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in C<sub>max </sub>of 53 % and in AUC of 26 % of celecoxib. The corresponding values in patients with moderate hepatic impairment were 41 % and 146 % respectively.&nbsp; The metabolic capacity in patients with mild to moderate impairment was best correlated to their albumin values. Treatment should be initiated at half the recommended dose in patients with moderate liver impairment (with serum albumin 25-35&nbsp;g/l). Patients with severe hepatic impairment (serum albumin &lt;25 g/l) have not been studied and celecoxib is contraindicated in this patient group.</p><p>&nbsp;</p><p>There is little experience of celecoxib in renal impairment.&nbsp; The pharmacokinetics of celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients. Thus caution is advised when treating patients with renal impairment. Severe renal impairment is contraindicated.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Celecoxib is mainly eliminated by metabolism. Less than 1&nbsp;% of the dose is excreted unchanged in urine. The inter-subject variability in the exposure of celecoxib is about 10-fold. Celecoxib exhibits dose- and time-independent pharmacokinetics in the therapeutic dose range. Elimination half-life is 8-12&nbsp;hours. Steady state plasma concentrations are reached within<strong><em> </em></strong>5&nbsp;days of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical safety data revealed no special hazard for humans based on conventional studies of repeated dose toxicity, mutagenicity or carcinogenicity beyond those addressed in section 4.4, 4.6, and 5.1 of the SmPC.</p><p>&nbsp;</p><p>Celecoxib at oral doses &sup3;150&nbsp;mg/kg/day (approximately 2‑fold human exposure at 200&nbsp;mg twice daily as measured by AUC<sub>0-24</sub>), caused an increased incidence of ventricular septal defects, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose‑dependent increase in diaphragmatic hernias was observed when rats were given celecoxib at oral doses &sup3;30&nbsp;mg/kg/day (approximately 6‑fold human exposure based on the AUC<sub>0-24</sub> at 200&nbsp;mg twice daily) throughout organogenesis. These effects are expected following inhibition of prostaglandin synthesis. In rats, exposure to celecoxib during early embryonic development resulted in pre‑implantation and post‑implantation losses, and reduced embryo/fetal survival.</p><p>Celecoxib was excreted in rat milk. In a peri-post natal study in rats, pup toxicity was observed.</p><p>&nbsp;</p><p>In a 2 year toxicity study an increase in nonadrenal thrombosis was observed in male rat at high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsules content </u></p><p>Lactose monohydrate</p><p>Sodium laurilsulfate</p><p>Povidone</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Capsule shells</u></p><p>Gelatin</p><p>Titanium dioxide E171</p><p>Sodium laurilsulfate</p><p>Sorbitan monolaurate</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>Indigotine E132</p><p>Shellac</p><p>Propylene glycol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Celebrex after the expiry date which is stated on the carton / Blister after EXP:. The expiry date refers to the last day of that month
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Store below 30<sup>&ordm;</sup>C. The sprinkled capsule contents on applesauce, rice gruel or yogurt are stable for up to 6 hours under refrigerated conditions (2-8&deg; C/ 35-45&deg; F).<strong> </strong>The sprinkled capsule contents on mashed banana should not be stored under refrigerated conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>100&nbsp;mg capsules</u><br />Blister pack containing 20 capsules</p><p><u>&nbsp;</u></p><p><u>200&nbsp;mg capsules</u><br />Blister pack containing 10 or 20 capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p><em>&nbsp;</em></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Saudi Limited 

MANUFACUTRED BY

Pfizer Saudi Limited for Celebrex 200 mg Capsules
Pfizer Pharmaceutical LLC, Vega Baja – PR- USA for Celebrex 100 mg Capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>